NCT00390234 - Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2011

Study Completion Date

August 31, 2013

Conditions

Fallopian Tube CancerFemale Reproductive CancerOvarian CarcinosarcomaOvarian SarcomaRecurrent Ovarian Epithelial CancerRecurrent Uterine SarcomaStage III Ovarian Epithelial CancerStage III Uterine SarcomaStage IV Ovarian Epithelial CancerStage IV Uterine SarcomaUterine CarcinosarcomaUterine Leiomyosarcoma

Interventions

DRUG

ziv-aflibercept

Given IV

Trial Locations (16)

19046

Fox Chase Cancer Center, Rockledge

48109

University of Michigan University Hospital, Ann Arbor

60201

Evanston CCOP-NorthShore University HealthSystem, Evanston

61603

Peoria Gynecologic Oncology, Peoria

91010

City of Hope, Duarte

95817

UC Davis Comprehensive Cancer Center, Sacramento

90033-0804

University of Southern California, Los Angeles

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

V5C 1M9

Vancouver General Hospital, Vancouver

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston

N6A 4L6

London Regional Cancer Program, London

M4N 3M5

Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

H2W 1S6

McGill University Department of Oncology, Montreal

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH